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1. Introduction 
Esophageal adenocarcinoma (EAC) affects approximately 17,000 individuals per year in the 
United States, is increasing in incidence, and is associated with an exceptionally high 
mortality rate. 1, 2 Overall five-year survival despite aggressive treatment in large, 
multidisciplinary oncology centers ranges between 15 and 25%. Poor outcome in patients 
with EAC is reflective of both deficiencies in early detection - the disease is typically 
diagnosed at an advanced (unresectable) stage - and the inadequacy of available standard 
therapies across stages.  Advanced/recurrent disease is incurable and carries a median 
survival of 9-12 months. Fully 50% of cases are metastatic at diagnosis, and cure rates with 
multimodality therapy for locally advanced disease do not exceed 40%--resulting in the 
majority of these patients eventually requiring palliative chemotherapy. Innumerable 
regimens have been studied. However, few are validated by phase III trials. Furthermore, 
trial eligibility ranges between histologies (Squamous cell carcinoma; SCC vs. 
Adenocarcinoma) as well as location in the upper gastrointestinal tract (distal esophagus, 
esophagogastric junction [EGJ], stomach). With these limitations in mind, there are a few 
guiding principles for treatment of advanced/metastatic disease. Chemotherapy is usually 
given in doublets and is chosen based on projected efficacy, patient performance 
status/medical co-morbidities, and side effect profile of the agents used. There is significant 
experience with combinations of cisplatin and 5-fluorouracil (5-FU), particularly with SCC, 
which are variously validated as better than best supportive care.3 More recently, with the 
epidemiologic shift from SCC to EAC, newer regimens focus on GEJ/gastric cancer, use 
three drugs and sometimes incorporate biologic/targeted therapies.  
2. Epidemiology and histology  
SCC has become increasingly less common, accounting for fewer than 30% of all esophageal 
malignancies in North America and many Western European countries.4 Although EAC is 
diagnosed predominantly in white men in whom the incidence has risen, EAC also is 
gradually increasing in men of all ethnic backgrounds and in women also.5 Several risk 
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factors for EAC have been established such as obesity and high body mass index (BMI).6-8 
Individuals in the highest quartile for BMI had a 7.6-fold increased risk of developing EAC 
compared with those in the lowest quartile, whereas SCC was not associated with BMI.9, 10 
Gastroesophageal reflux disease (GERD) and Barrett’s esophagus are the other two major 
risk factors for EAC.11-15 GERD is associated with high BMI and is also a risk factor for 
Barrett’s esophagus. Barrett’s esophagus is a condition in which the normal squamous 
epithelium of the esophagus that damaged by GERD is replaced by a metaplastic, columnar, 
or glandular epithelium of the esophagus that is predisposed to malignancy.15 Patients with 
Barrett’s esophagus have 30 to 60 times of greater risk of developing EAC than the general 
population.13   
3. Staging 
The American Joint Committee on Cancer (AJCC) staging classification has revised in 2010.16 
The tumor (T), node (N), and metastasis (M) classification developed by AJCC 2002 was 
based on pathologic review of the surgical specimen in patients who had surgery as primary 
therapy. The revised 2010 AJCC staging classification is based on the risk-adjusted random 
forest analysis of the data generated by the Worldwide Esophageal Cancer Collaboration 
(WECC) in 4627 patients who were treated with esophagectomy alone without induction or 
postoperative therapy. The revised version includes separate stage grouping for SCC and 
EAC (table 1.). The revised staging system is for the esophageal and EGJ cancers, including 
cancer within the first 5cm of the stomach that extends into the EGJ or distal thoracic 
esophagus. T4 disease is sub-classified into T4a (potentially resectable) and T4b 
(unresectable). Staging and evaluation for respectability requires endoscopic ultrasound 
(EUS) for T staging (focusing on the possibility of T4 disease), computed tomography (CT), 
and [18F]-2-deoxy-D-glucose positron emission tomography (FDG-PET), which is often 
integrated with CT (PET/CT).  
3.1 Esophagogastric junction (EGJ) 
In the revised AJCC staging system, tumors whose midpoint is in the lower thoracic 
esophagus, EGJ or within the proximal 5cm of the stomach that extends into the EGJ or 
esophagus, are classified as adenocarcinoma of the esophagus for the purposes of staging. 
All other cancers with a midpoint in the stomach lying more than 5cm distal to the EGJ, or 
those within 5cm of the EGJ but not extending into the EGJ or esophagus are staged using 
the gastric cancer staging system.  
 
Primary tumor (T) 
TX primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis High grade dysplasia 
T1 Tumor invades lamina propria, mucularis mucosae, or submucosa 
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Primary tumor (T) 
T1a Tumor invades lamina propria, mucularis mucosae 
T1b Tumor invades submucosa 
T2 Tumor invades muscularis propria 
T3 Tumor invades adventitia 
T4 Tumor invades adjacent structures 
T4a Resectable tumor invading plura, pericardium, or diaphragm 
T4b Unresectable tumor invading other adjacent structures, such as aorta, vertebral 
body, trachea, etc 
Regional lymph nodes (N) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1-2 regional lymph nodes 
N2 Metastasis in 3-6 regional lymph nodes 
N3 Metastasis in seven or more regional lymph nodes 
Distant metastasis (M) 
M0 No distant metastasis 
M1 Distant metastasis 
Histologic grade (G) 
GX Grade cannot be assessed - stage grouping as G1 
G1 Well differenciated 
G2 Moderately differenciated 
G3 Poorly differentiated 
G4 Undifferentiated - stage grouping as G3 squamous 
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Adenocarcinoma 
Stage T N M Grade 
0 Tis (HGD) N0 M0 1, X 
IA T1 N0 M0 1-2, X 
IB T1 N0 M0 3 
 T2 N0 M0 1-2, X 
IIA T2 N0 M0 3 
IIB T3 N0 M0 Any 
 T1-2 N1 M0 Any 
IIIA T1-2 N2 M0 Any 
 T3 N1 M0 Any 
 T4a N0 M0 Any 
IIIB T3 N2 M0 Any 
IIIC T4a N1-2 M0 Any 
 T4b Any M0 Any 
 Any N3 M0 Any 
IV Any Any M1 Any 
Table 1. AJCC 2010 TNM staging of esophagogastric junction (EGJ) adenocarcinoma. 
4. Current therapy for resectable esophageal adenocarcinoma 
EMR or ablation are good primary treatment options for patients with Tis and T1a tumors 
where as esophagectomy is still preferred treatment for T1a tumor. For patients with T1b, 
esophagectomy is the preferred treatment option for those with non-cervical cancer. 
Chemoradiation therapy is the preferred treatment for patients with cervical cancer.17 
Primary treatment options for patients with locally advanced resectable esophageal cancer 
include preoperative chemoradiation therapy, definitive chemoradiation therapy, 
preoperative chemotherapy, or esphagectomy.  
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4.1 Chemoradiation therapy 
Since the overall poor survival rates of patients who have been treated with resection alone, 
multiple modalities have been used for the treatment of esophageal cancer. Concomitant 
chemotherapy and radiation therapy has been studied in the preoperative setting and as 
definitive nonoperative treatment.  
4.1.1 Preoperative concurrent chemoradiation therapy 
Preoperative chemoradiation followed by surgery is the most common approach for 
patients with resectable esophageal cancer. Several trials have directly compared surgery 
with or without preoperative chemoradiation therapy for patients with potentially 
resectable esophageal cancer.18-24 Of the five completed randomized trials compared 
preoperative concurrent chemoradiation therapy versus surgery alone, only two showed a 
statically significant survival benefit for chemoradiation therapy.23, 24 Walsh et al.23 
randomized 113 patients with esophageal or EGJ adenocarcinoma to receive either surgery 
alone or preoperative chemoradiation therapy. The chemoradiation therapy consisted of 
two courses of cisplatin (75 mg/m2 on day 7 of each cycle) and 5-fluorouracil (15mg/kg by 
bolus days 1 to 5), and radiation therapy was administered in 15 fractions over a three week 
period to a total of 40 Gy. Only one of the cycles of chemotherapy was actually given 
concurrently with the radiation. The combined-modality therapy provided a significant 
improvement in median survival (16 versus 11 months; p =0.01) and in three year survival 
(32% versus 6 %) compared with surgery alone. These results were criticized because of the 
lower than expected survival with surgery alone.  
In the phase III multicenter CROSS trial from the Netherlands24, 364 patients with 
potentially resectable (T2-3, N0-1, M0) esophageal or EGJ cancer were randomized to 
surgery alone or weekly paclitaxel 50 mg/m2 plus carboplatin [AUC =2] on days 1, 8, 15, 22, 
and 29, administered with concurrent radiotherapy with 41.4 Gy in 23 fractions over five 
weeks. Surgery was conducted within 6 weeks of completing chemoradiation therapy. The 
median survival of patients who received preoperative chemoradiation therapy and surgery 
was 49 months, compared to 26 months for those who received surgery alone. When 
adjusted for baseline covariates, the hazard ratio was 0.66 (p = 0.008). After a median follow-
up of 32 months, the 1-,2- and 3-year survival rates were 82 percent, 67 percent and 59 
percent, respectively, for chemoradiation therapy plus surgery verses 70 percent, 52 percent, 
and 48 percent for surgery alone with 0.67 of hazard ratio (p = 0.011). In a preliminary report 
presented at the 2010 ASCO meeting, preoperative chemoradiation therapy was well 
tolerated, with the only grade 3 or higher toxicity being leucopenia (7%). The complete (R0) 
resection rate was higher with chemoradiation therapy (92 vs. 65%), and 33 % of those 
treated with chemoradiation therapy had a pCR.   
In contrast, three other trials have not shown a significant survival advantage for this 
approach. In the trial from University of Michigan19, 100 patients with locoregional 
esophageal or EGJ cancer were randomly assigned to surgery with or without preoperative 
chemoradiation therapy with cisplatin, 5-FU and vinblastine. A pCR was observed in 28 
percent of patients after preoperative treatment. At a median follow-up of 8.2 years, the 
median survival was similar (16.9 vs. 17.6 months for multimodality therapy and surgery 
respectively). However, three-year survival was nearly twice higher in chemoradiation 
therapy (30% vs. 16%), although there was no statistically significant.  
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The CALGB 9781 trial24 was a prospective randomized Intergroup trial comparing 
trimodality therapy with surgery alone in 500 patients with stage I through III esophageal 
or EGJ cancer. Patients were staged with upper endoscopy, barium esophagram, and CT. 
Staging EUS and thoracoscopy/laparoscopy were encouraged. Due to poor accrual, the 
study fell short prematurely with only 56 patients enrolled. Those patients were 
randomized to undergo either surgery alone or concurrent chemoradiation therapy with 
cisplatin and 5-fluorouracil. A pCR was achieved in 10 of 25 assessable patients in the 
trimodality therapy (40%), and neither perioperative morbidity nor mortality was 
increased compared to surgery alone. Patients receiving trimodality therapy also had a 
better 5-year survival rate (39% vs. 16%), although the difference was not statistically 
significant.  
The benefit of preoperative chemoradiation therapy in smaller resectable tumors was 
addressed in the French FFCD 9901 trial25, which randomly assigned 195 patients with stage 
I or II esophageal or EGJ cancer to preoperative chemoradiation therapy (cisplatin plus 5-FU 
and concurrent radiation therapy [45Gy]) versus surgery alone. In a preliminary report of an 
interim analysis, at a median follow-up of 69 months, preoperative chemoradiation therapy 
did not improve median overall survival (32 vs. 44 months with surgery alone), and it was 
associated with significantly more serious adverse events (65% vs. 35% ) and a significantly 
higher rate of perioperative mortality (7.3% vs. 1.1%). Full publications of these data are 
awaited. 
A meta-analysis of randomized trials comparing preoperative chemoradiation therapy 
versus surgery alone included 1116 patients enrolled on nine trials26. When compared to 
surgery alone, there was only a nonsignificant trend towards improved survival with 
chemoradiation therapy (odds ratio 0.79, 0.77, and 0.66 for one-, two- and three-year 
mortality, respectively). The improvement in three-year survival was statistically significant 
when the analysis was restricted to trials of concurrent chemoradiation therapy (odds ratio 
for mortality 0.45, 95% CI 0.26-0.79). A second meta-analysis of 10 randomized comparing 
preoperative chemoradiation therapy and surgery alone showed same conlusion27. 
Compared to surgery alone, preoperative chemoradiation therapy was associated with 
significantly better two-year all cause mortality (hazard ratio 0.81, 95% CI 0.70-0.93). This 
corresponded to a 13 percent absolute difference in survival at two years.  
In brief summary, with several trials and at least two meta-analyses demonstrating better 
survival with preoperative concurrent chemoradiation, the majority of patient potentially 
resectable localized cancer of the thoracic esophagus and EGJ now undergo some form of 
combined modality therapy rather than local therapy alone.  
4.1.2 Preoperative sequential chemoradiation therapy 
Several trials comparing sequentially administered chemotherapy and radiation therapy 
followed by surgery to surgery alone have failed to show any survival advantage to 
combined modality therapy.18, 20, 21 
4.1.3 Definitive chemoradiation therapy 
In randomized studies, the addition of cisplatin-based chemotherapy to radiation therapy 
significantly improves survival over radiation alone, however, the available data are almost 
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exclusively in SCC, and none of the trials have performed adequate pretreatment staging to 
reliably correlate outcome with locoregional tumor extent such as locally advanced 
unresectable versus potentially operable disease.28-30  
In the RTOG 85-01 trial, patients with locoregional thoracic esophageal SCC or AC received 
4 cycles of 5-FU and cisplatin. Radiation therapy (50Gy) was administered concurrently with 
day 1 of chemotherapy28. The control therapy arm was radiation therapy alone which was 
higher dose (64Gy) than I the combined modality therapy arm. Patients who were randomly 
assigned to receive combined modality therapy showed a significant improvement in both 
median survival (14 vs. 9 months) and 5-year overall survival (27% vs. 0%) with projected 8- 
and 10-year survival rates of 22% and 20%, respectively29. As a result of this trial, definitive 
chemoradiation therapy became the standard care for patients with inoperable disease even 
though 90 percent of patients had SCC.  
The US Intergroup Study 0123 (INT 0123) was designed as the follow-up trial to RTOG 85-
0131. The trial compared two different radiation doses (50.4 Gy or 64.8 Gy) used with the 
same chemotherapy regimen as RTOG 85-01 (cisplatin and 5-FU). 236 Patients with 
nonmetastatic SCC (85%) and AC (15%) of the thoracic esophagus were randomly assigned. 
No significant difference was observed in median survival (13.0 vs. 18.1 months), two-year 
survival (31% vs. 40%), and locoregional failure or locoregional persistence of cancer (56% 
vs. 52%) between the high-dose and standard-dose radiation therapy groups. High-dose 
radiation therapy was significantly more toxic.  
After the results of these studies, definitive chemoradiation therapy with 5-FU and cisplatin 
using the radiation therapy dose of 50.4 Gy was established as the standard approach for 
patients with esophageal cancer. 
4.1.4 Postoperative chemoradiation therapy 
In a phase II nonrandomized trial evaluating postoperative concurrent chemoradiation with 
cisplatin and 5-FU in patients with poor prognosis esophageal and EGJ cancers, the 
projected rates of 4-year overall survival, freedom from recurrence, distant metastatic 
control, and locoregional control were 51%, 50%, 56%, and 86%, respectively32. However, the 
efficacy of postoperative chemoradiation therapy has not been compared with surgery alone 
in a randomized trial involving patients with esophageal cancer.  
The Intergroup trial SWOG 9008/INT-0116 investigated the effect of surgery and 
postoperative chemoradiation therapy on the survival of patients with resectable 
adenocarcinoma of the stomach (80%) or EGJ (20%)33. 556 patients were randomly 
assigned to surgery plus postoperative chemoradiation therapy (leucovorin and 5-FU) or 
surgery alone. Median overall survival in the surgery alone was 27 months compared 
with 36 months in the postoperative chemoradiation group. The postoperative 
chemoradiation group had better 3-year survival rates (50% vs. 41%) and significantly 
improved overall survival for all patients. A major criticism of this study is that surgery 
was not part of this protocol. Moreover, 54% of patients had a D0 resection, 36% had a D1 
resection, and only 10% had a D2 resection. However, the results of this study have 
established postoperative chemoradiation therapy as a reasonable option of patients with 
EGJ adenocarcinoma. 
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4.2 Chemotherapy  
4.2.1 Preoperative chemotherapy 
Several randomized trials have evaluated the benefit of preoperative chemotherapy in 
patients with esophageal cancer limited to the primary and regional nodes by clinical 
assessment34-39.  
In the US Intergroup trial 0113, 467 patients with potentially resectable esophageal or EGJ 
cancer were randomly assigned to surgery alone or preoperative chemotherapy with 
cisplatin and 5-FU followed by surgery34. The majority of patients had adenocarcinoma 
(55%) and outcomes were similar for both histologies. The preliminary results did not show 
any survival benefit between the groups. In a later update of long-term outcomes (median 
follow-up with 8.8 years), preoperative chemotherapy decreased the incidence of R1 
resection (4% vs. 15% in the surgery alone group), however, no improvement was seen in 
overall survival between the groups.  
In contrast to Intergroup 0113, a couple of trials suggest a survival benefit for preoperative 
chemotherapy compared to surgery alone. The Medical Research Council (MRC) OEO2 trial 
randomly assigned 802 patients with AC (69%) or SCC (31%) of the esophagus to surgery 
alone or preoperative chemotherapy with cisplatin and 5-FU39. At a median follow-up of 6 
years, disease-free and overall survivals were significantly longer for the preoperative 
chemotherapy group. The 16 percent reduction in the risk of death favoring chemotherapy 
translated into a significant improvement in five year survival (23 vs. 17%).  
The phase III study conducted by the French Study group (FNLCC ACCORD07-FFCD 9703) 
compared preoperative chemotherapy (5-FU and cisplatin) followed by surgery with 
surgery alone40. 224 patients with potentially resectable stage II or greater adenocarcinoma 
of EGJ (n=144), distal esophagus (n=25), or stomach (n=55) were randomly assigned.  
At a median follow-up of 5.7 years, 3- and 5- year overall survival rates were 48% and 38%, 
respectively, for patients with preoperative chemotherapy compared with 35% and 21%, 
respectively, for those with surgery alone.  
In a meta-analysis of eight randomized trials of surgery alone or preoperative chemotherapy 
followed by surgery for esophageal cancer (1724 patients, any histology, excluding cervical 
esophageal cancers) suggested a small survival benefit for preoperative chemotherapy 
group27. The hazard ratio for all cause survival at two years favored chemotherapy followed 
by surgery (hazard ratio for all-cause mortality 0.90, 95% CI 0.81-1.0), a difference which 
translated into a two-year absolute survival benefit of 7 percent. There was no significant 
benefit for chemotherapy for patients with SCC, however, with patients with EAC, there 
was a significant benefit, which was based on data from the United Kingdom MRC OEO2 
trial.  
4.2.2 Perioperative chemotherapy 
Investigators with the MRC conducted a second study of preoperative chemotherapy38. In 
contrast to the previous MRC study (MRC OEO2 trial), they included patients with 
resectable gastric (74%), EGJ (15%), or distal esophageal adenocarcinoma (11%). This UK 
MAGIC trial evaluated the effect of perioperative chemotherapy with the ECF (epirubicin, 
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cisplatin, and 5-FU) regimen given before and after surgery in resectable gastroesophageal 
cancer. A total of 503 patients were randomly assigned to surgery with or without 
perioperative chemotherapy. Most of the patients had gastric cancer (74%), while small 
group of patients had adenocarcinoma of lower esophagus (14%) and EGJ (11%). At a 
median follow-up of four years, 5-year overall survival was significantly better in the 
perioperative chemotherapy group compared with surgery alone (36 vs. 23%).  
5. Current therapy for unresectable and metastatic esophageal 
adenocarcinoma 
The goals of therapy for patients with advanced unresectable and metastatic esophageal 
cancer are to palliate symptoms, including malignant dysphagia, and improve survival. 
Patients with advanced adenocarcinoma of esophagus and EGJ can be treated using the 
regimens included in the gastric cancer guide-lined for advanced gastric cancer. Since the 
mid 1970s, the incidence of SCC in the United States has been declining, while the incidence 
of adenocarcinoma in white males rose by 350 percent from 1970s to 1990s41. 
Adenocarcinoma became the dominant histology in the early 1990s. In addition, the 
incidence of distal gastric adenocarcinoma declined, while the incidence of adenocarcinoma 
of EGJ and proximal stomach has increased. The increasing incidence has paralleled the rise 
in incidence of EAC. These histories suggest that adenocarcinomas of the distal esophagus, 
EGJ and proximal stomach share a common pathogenesis.   
5.1 Chemotherapy for advanced unresectable or metastatic esophageal 
adenocarcinoma 
In randomized clinical trials, no consistent benefit was seen for any specific chemotherapy 
regimen, and chemotherapy showed no survival benefit compared with best supportive care 
for patients with advanced esophageal cancer3. However, palliative chemotherapy may 
improve quality of life in patients with unresectable or metastatic esophageal cancer.  
5.1.1 Single agent 
Cisplatin is one of the most active agents, with a single-response rate consistently in the 
range of 20% or greater42. Newer agents such as irinotecan43-45, docetaxel46, 47, paclitaxel48-50, 
and etoposide51 have also shown activity as single agents in advanced esophageal cancer. 
5.1.2 Combination chemotherapy 
The combination of cisplatin and fluorouracil has been one of the most commonly used 
regimens in both metastatic and localized esophageal cancer due to its activity and well-
established toxicity profile. Cisplatin also has been combined with taxanes50, 52-54, 
irinotecan55, mitomycin56, and gemcitabine57, 58.  
Capecitabine is designed oral fluoropyrimidine that is converted to 5-FU in three-step 
enzymatic process59. In the REAL-2 trial60, multicenter phase III study assessed by a 
randomized 2x2 design, 1002 patients with histologically confirmed EAC, SCC, or 
undifferentiated cancer of esophagus, EGJ, or stomach randomly assigned to receive one of 
four epirubicin-based regimens ([ECF]; epirubicin, cisplatin, 5-FU,  [EOF]; epirubicin, 
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oxaliplatin, 5-FU, [ECX]; epirubicin, cisplatin, capecitabine, [EOX]; epirubicin, oxaliplatin, 
capecitabine). The primary outcome in this study was non-inferiority in overall survival. 
The primary endpoint was reached and there was a trend toward better overall survival for 
the capecitabine and oxaliplatin groups.  
Regimens containing irinotecan have been studied. Irinotecan has been combined with 
cisplatin61, docetaxel62, and fluoropyrimidines63. Irinotecan plus cisplatin is active and well 
tolerated in several studies. Combinations of irinotecan and docetaxel with or without 
cisplatin are active but toxic. Combinations of irinotecan and oxaliplatin are highly 
efficacious and tolerated63. There are no phase III trials comparing an irinotecan-based 
combination with a cisplatin-based regimen.  
Tables show brief regimens listed in the guidelines for metastatic or locally advanced 
esophageal or EGJ cancers (Table 2 and 3). 
 
First-line therapy 
DCF or its modifications (category 1 for docetaxel, cisplatin, and fluorouracil; category 2B 
for docetaxel, carboplatin, and fluorouracil; category 2A for all other combinations 
ECF or its modifications (category 1) 
Fluoropyrimidine- or taxane-based regimens, single agent or combination therapy, 
(category 1 for combination of fluoropyrimidine and cisplatin; category 2A for all other 
regimens) 
Trastuzumab with chemotherapy (category 1 for combination with cisplatin and 
fluoropyrimidine; category 2B for combination with other chemotherapy agents) for 
patients who are HER2-neu positive, as determined by a standardized method. 
Table 2. First-line therapy for Recurrent and Metastatic Esophageal Cancer. 
 
Second-line therapy 
Trastuzumab with chemotherapy (category 1 for combination with cisplatin and 
fluoropyrimidine; category 2B for combination with other chemotherapy agents) for 
patients who are HER2-neu-positive, if not used as first-line therapy 
Docetaxel or paclitaxel (category 2B) 
Irinotecan-based single-agent or combination therapy (category 2B) 
Table 3. Second-line therapy for Recurrent and Metastatic Esophageal Cancer. 
6. Biological/Targeted therapy 
With the recent development of small molecules and antibodies designed form biologic first 
principles, biologic/targeted therapies are now incorporating with chemotherapy. The most 
commonly used agents include angiogenesis inhibitors (bevacizumab) and epidermal growth 
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factor receptor inhibitors (panitumumab, cetuximab, erlotinib). Shah et al. carried out a phase 
II trial of 47 patients to study the addition of the anti-vascular endothelial growth factor 
monoclonal antibody, bevacizumab, to weekly cisplatin and irinotecan in patients with 
advanced gastroesphageal cancer.64 The median survival was 12.3 months (95% CI, 11.3 to 17.2 
months), and there was no increase in chemotherapy related toxicity. The ongoing REAL-3 
trial is testing epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in 
previously untreated advanced esophagogastric cancer. Pittsburgh group is carrying a phase II 
study of irinotecan plus panitumumab as second line treatment for advanced EAC. In the 
setting of locally advanced disease, ECOG 2205 investigated the addition of cetuximab to 
chemoradiation therapy for resectable EAC, and ACOSOG Z4051 is enrolling patients with 
adenocarcinoma to chemoradiation therapy plus panitumumab.  
The revolution in biological/targeted therapies offers hope for improvement in survival for 
patients with advanced EAC. However, historically, the empiric addition of targeted agents 
such as cetuximab and bevacizumab to cytotoxic chemotherapy has yielded a modest 
improvement in survival for patients with solid tumors.65-67 This relative failure of the 
current approach has led to great interest in either selecting patients for therapies or 
selecting therapies for patients, usually by tumor profiling and selective preclinical 
models.68, 69 This project aims to test a novel direct translational model of target selection 
and inhibition with the goal of furthering the rational selection of targeted therapies for 
patients with advanced EAC.  
6.1 Trastuzumab 
HER2 is another member of the EGFR family that is associated with cell proliferation, 
migration, and differentiation. HER2 over-expression and/or amplification have been 
reported in EAC, along with some evidence supporting a prognostic utility. Various phase I 
and II trial have reported a possible benefit for HER2 blockage70, 71. Data from these trials 
served as the basis for a recent prospective phase III trial (ToGA)72 that evaluated the 
therapeutic benefit of blocking this target in a randomized fashion.  
In the ToGA trial, more than 594 patients with HER2-positive gastric and gastroesophageal 
cancer were treated with standard chemotherapy (infusional 5-FU or capecitabine plus 
cisplatin), either with or without trastuzumab. The tumors of the enrolled patients were 
either fluorescence in situ hybridization (FISH)-positive or positive for HER2 expression by 
immunohistochemistry (IHC). At a median follow-up of 17.1 to 18.6 months, median overall 
survival (the primary endpoint) was significantly improved with the addition of 
trastuzumab (13.8 vs. 11.1 months). Safety profiles were comparable, with no unexpected 
adverse events in the trastuzumab group and no difference was seen in symptomatic 
congestive heart failure between the arms. This establishes trastuzumab plus chemotherapy 
as a new standard of care for the treatment of patients with HER2-expressing advanced 
gastric and EGJ adenocarcinoma.  
6.2 Cetuximab 
As monotherapy, cetuximab, a monoclonal antibody targeting the EGFR, has limited activity 
as second-line therapy73. The safety and efficacy adding cetuximab to first-line 
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chemotherapy has been tested in several studies of advanced esophagogastric cancer74, 75. 
All suggest that this approach is safe and in some cases, objective response rates are over 50 
percent and median survival is less than 10 months. Conclusions regarding the clinical 
utility of cetuximab in patients with advanced esophagogastric cancer need data from 
randomized phase III trial. 
6.3 Gefitinib and erlotinib (small molecule tyrosine kinase inhibitors) 
Another means of interfering with EGFR signaling is through the use of orally active 
tyrosine kinase inhibitors (TKIs), small molecules that block the binding site of the EGFR 
tyrosine kinase. Small molecule TKIs such as Gefitinib and Erlotinib have been tested as 
single agents in phase II trials in esophagogastric cancer.  
In a phase II study of gefitinib in 36 patients who had failed one prior therapy for advanced 
esophageal cancer, there was only one partial response, but 10 patients had stable disease 
for at least eight weeks. Treatment was reasonably well tolerated76.  
In another trial, gefitinib was administered to 27 patients with advanced unresectable EAC. 
There were three partial responses, and seven had stable disease77.  
In SWOG trial, 70 patients with unresectable or metastatic adenocarcinoma originating in 
the EGJ or stomach received first line treatment with erlotinib78. Six patients had an objective 
response rate (9 percent, one complete), all of them were EGJ tumors. There was no 
molecular parameter of EGFR expression or mutations were predictive of clinical outcome. 
The reason for the apparent differential sensitivity of EGJ and gastric cancer s to EGFR 
blockade using erlotinib is unclear. 
6.4 Bevacizumab 
Elevated serum and tumor levels of vascular endothelial growth factor (VEGF) are 
associated with a poor prognosis in patients with resectable gastric cancer79, 80. Adding the 
anti-VEGF monoclonal antibody bevacizumab to chemotherapy in advanced upper GI 
cancer has been studied. 
In the phase III AVAGAST trial, in which 774 patients with previously untreated locally 
advanced unresectable or metastatic gastric or EGJ cancer were randomly assigned to 
capecitabine plus cicplatin with either bevacizumab or placebo81. In a preliminary report, 
there was no significant benefit from bevacizumab in median overall survival (the primary 
endpoint, 12.1 vs. 10.1 months, hazard ratio 0.87, 95% CI 0.73-1.03) although the use of 
bevacizumab significantly improved both objective response rate and median progression-
free survival.  
7. Conclusion 
The treatment of esophageal and EGJ cancer has undergone a major evolution over the past 
decades.  However, the optimal therapy for these patients is still controversial.  Although 
several advances have made in staging procedures and therapeutic approaches, esophageal 
cancer is often diagnosed late. Some forms of multimodal management are essential for 
treating patients with esophageal cancer.  Most of the clinical studies have not differentiated 
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between SCC and adenocarcinoma so that most of approaches are similar for both 
histologies. However, there are an increasing amount of evidence supports the view that 
they differ in terms of their epidemiology, biology, and prognosis, etc.  In recognition of 
these differences, the AJCC 2010 TNM staging criteria provides separate stage groupings for 
SCC and adenocarcinomas of the esophagus and EGJ. For patients with locally advanced 
resectable adenocarcinoma of esophagus and EGJ (T1b or higher, any N), primary treatment 
options include preoperative chemoradiation therapy, definitive chemoratiation, 
preoperative chemotherapy, or esophagectomy. Postoperative treatment is based on their 
staging. Fluoropyrimidine-based chemoradiation therapy is recommended for patients with 
node-positive adenocarcinoma of esophagus and EGJ. Perioperative chemotherapy is 
recommended for patients with completely resected adenocarcinoma of EGJ (MAGIC trial). 
All patients with residual disease at surgical margins may be treated with fluoropyrimidine-
based chemoradiation. For patients with unresectable disease or those with resectable 
disease who choose not to undergo surgery, fluoropyrimidine- or taxane-based concurrent 
chemoradiation therapy is recommended. For patients with recurrent and metastatic 
disease, the goals of chemotherapy are to palliate symptoms and improve survival. 
Biologic/Targeted therapies have produced encouraging results in the treatment of patients 
with advanced adenocarcinoma of esophagus and EGJ. The efficacy of these new therapies 
in combination with chemotherapy still need results from randomized phase III trials.  
Considerable advanced have been made in the treatment of adenocarcinoma of esophagus 
and EGJ. Novel therapeutic modalities, such as targeted therapies, antiangiogenic agents, 
gene therapy, and etc are being studied in clinical trials. More tailor-made treatment for 
patients with esophageal cancer may be needed and well-designed clinical trials are awaited 
to enable further advances. 
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